Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6267626 | 0.81 | MEN1 (0.33) | MAPTSMN1; SMN2 | |
| SCHEMBL7058798 | 0.73 | EHMT2 (0.42) | MAPTHPGD | |
| SCHEMBL2458873 | 0.72 | POLB (0.39) | MAOAMAOBSMN1; SMN2HSD17B10SLC6A4 | |
| SCHEMBL23865031 | 0.71 | CXCL12 (0.32) | MAOAMAOBMAPTHPGDSMN1; SMN2 | |
| SCHEMBL2562634 | 0.67 | — | — | |
| SCHEMBL13476262 | 0.65 | HPGD (0.33) | MAOAMAOBMAPTHPGDSMN1; SMN2 | |
| SCHEMBL15526665 | 0.64 | MAPT (0.32) | MAOAMAOBMAPTHPGDSMN1; SMN2 | |
| SCHEMBL6041001 | 0.64 | ALDH1A1 (0.35) | MAPT | |
| Diphenylsulfane SCHEMBL452 | 0.64 | HPGD (0.60) | MAOAMAOBMAPTHPGDSMN1; SMN2 | |
| Diphenylsulfane SCHEMBL28332331 | 0.64 | HPGD (0.60) | MAOAMAOBMAPTHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309762-A1 | CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2012-12-06 | — | — | US | disclosed |
| WO-2012087630-A1 | PYRIDINE AND PYRIMIDINE COMPOUNDS FOR CONTROLLING INVERTEBRATE | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-06-28 | — | — | WO | disclosed |
| EP-2182945-A1 | ANIMAL PEST CONTROL METHOD | E. I. Du Pont de Nemours and Company (US) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009003075-A1 | ANIMAL PEST CONTROL METHOD | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309762-A1 | CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF | CYP3A43, CYP3A5, POR | MAOA 62/4885MAOB 61/4885MAPT 2964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.